Oryzon Genomics Sa

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in and has offices in Spain and the United States.